Antoine G, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396, 1998. PubMed: 9601507
Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89: 10847-10851, 1992. PubMed: 1438287
Meyer H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038, 1991. PubMed: 2033387
Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berlin Munch. Tierarztl. Wochenschr. 107: 253-256, 1994.
Mayr A, et al. Abstammung, eigenschafter und verwendung des attenuierten vaccinia-stammes. Infection 3: 6-14, 1975.
Rotz LD, et al. Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb. Mortal. Wkly. Rep. 50: 1-25, 2001.
or colder
Wyatt LS, et al. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251: 334-342, 1998. PubMed: 9837798
MVA was isolated by serial passage of CVA (Ankara) strain in chick embryo fibroblasts (CEF) in the laboratory of Professor Anton Mayr, then given to the National Insitutes of Health, where it was plaque purified three times in CEF cells. VR-1566 was derived by limited further passage of stock received from the NIH in the SL-29 chicken embryo fibroblast cell line [ATCC CRL-1590].
or colder
|
